Barclays PLC Seagen Inc. Transaction History

Barclays PLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 07, 2023	SELL	$191.51 - $216.16 $55.5 Million - $62.7 Million	-290,050 Reduced 14.02%	1,779,070 $377 Million
Q2 2023 Aug 03, 2023	BUY	$187.64 - $206.25 $347 Million - $381 Million	1,846,680 Added 830.19%	2,069,120 $398 Million
Q1 2023 May 04, 2023	SELL	$127.59 - $203.08 $18.6 Million - $29.7 Million	-146,066 Reduced 39.64%	222,440 $45 Million
Q4 2022 Feb 13, 2023	BUY	$117.37 - $139.17 $6.8 Million - $8.07 Million	57,956 Added 18.66%	368,506 $47.4 Million
Q3 2022 Nov 03, 2022	BUY	$135.27 - $180.11 $515,513 - $686,399	3,811 Added 1.24%	310,550 $42.5 Million

Q2 2022 Aug 12, 2022	BUY	$108.81 - $179.33 $19.7 Million - $32.5 Million	181,441 Added 144.81%	306,739 $54.3 Million
Q1 2022 May 16, 2022	BUY	$119.61 - $157.85 $15 Million - $19.8 Million	125,298 New	125,298 $18.1 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.